Infinity Pharmaceuticals And IPI-145: ASCO 2013 Highlights
Seeking Alpha
In June 2012, Infinity suffered a significant writedown when its cancer drug, saridegib proved ineffective in a Phase II clinical trial. The company restructured financing deals with Takeda Pharmaceutical Company, Purdue Pharmaceutical Products, and ...
http://seekingalpha.com/article/1491062-infinity-pharmaceuticals-and-ipi-145-asco-2013-highlights?source=google_news
 |
BY WORLD DRUG TRACKER
No comments:
Post a Comment